Camelina’s Genetic Blueprint: Unraveling Subgenome Dominance and Population Structure
Newswise — Camelina sativa, also known as false-flax, is gaining attention as a biofuel crop due to its…
From Genome to Action: Pathobase Transforms Zoonotic Pathogen Tracking
Newswise — Zoonotic pathogens, capable of crossing between animals and humans, pose escalating threats due to antimicrobial resistance,…
How a Single Gene Shapes the Floral Elegance of the “April Snow” Tree
Newswise — Ornamental trees such as Chionanthus retusus enrich landscapes worldwide, valued for their abundant spring blossoms and…
Yale Genetics Faculty Berna Sozen and Steven Reilly Named 2025 Pew Biomedical Scholars
Newswise — The Yale School of Medicine Department of Genetics is proud to announce that two of its…
Health-care deal creates $6 billion company aiming to upend drug middlemen
John Tozzi | Bloomberg Eversana, a company that helps drugmakers sell their medicines, has acquired a smaller firm…
Genetic Study Suggests Ways to Catch Blood Cancer Earlier
Newswise — As we age, our cells replicate, and the DNA in these cells can acquire mistakes —…
Cancer’s Progress Detailed by 3D Genomic Maps
Newswise — Researchers have long known that cancer alters its genome as it evolves. What has been less…
News Tips: Basic Scientists at Johns Hopkins Medicine Study mRNA Technology to Develop Promising Treatments
FOR IMMEDIATE RELEASE Newswise — Harnessing the power of mRNA, a naturally occurring molecule that tells the body…
IU Rare Disease Clinic Solves Toughest Medical Cold Cases
The IU Impact: We bring hope to families by providing answers for their ultra-rare medical mysteries and use…
Economic uncertainty stunts funding to San Diego startups
Investments in San Diego County startups decreased by 35% in the second quarter compared to a year ago,…
Double trouble: gene-regulating duo shapes cell fate and disease
Newswise — CLEVELAND—Shedding light on what determines how cells become what they are meant to be—nerves, bone, muscles,…
RFK Jr. Is Supporting mRNA Research—Just Not for Vaccines
One of the targeted recipients, Tiba Biotech, had a $750,000 contract with BARDA that was slated to end…